/
/
Celgene's Revlimid now approved for Multiple Myeloma in Japan
Celgene's Revlimid now approved for Multiple Myeloma in Japan image
Celgene's Revlimid now approved for Multiple Myeloma in Japan
Posted Dec 23, 2015

Read the original Celgene announcement

Celgene's Revlimid (lenalidomide) can now be used with dexamethasone for relapsed or refractory multiple myeloma patients who have received at least one prior treatment in Japan.

The approval was based on the FIRST trial, an international randomized Phase III trial. A Japanese Phase II study MM-025 confirmed the decision.

There are more than 11,000 men and women in Japan currently undergoing treatment for multiple myeloma, and approximately 4,000 are newly diagnosed each year.

According to Business Finance News, this is the first myeloma drug approved in Japan. Celgene will now work with Japanese authorities to determine next steps for pricing and reimbursement.

This provides an expansion for Revlimid which is currently approved in combination with dexamethasone in nearly 50 countries including those in Europe. the Americas, the Middle-East and Asia and in combination with dexamethasone for patients who have progressed having one prior therapy in Australia and New Zealand.

For more information about Revlimid or the Celgene RevAssist program, click here.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811